Search research articles
Contact Us
Filters
Showing results (41-50 of 178) with videos related to
Page
of 18
Sort By:
Progress in Neurobiology
|
September 1, 2011
The serotonergic system in Parkinson's disease
Philippe Huot, Susan H Fox, Jonathan M Brotchie
Neurologic Clinics
|
April 4, 2025
Experimental Therapeutics in Parkinson's Disease: A Review
Priti Gros, Laura Armengou Garcia, Susan H Fox
JAMA Neurology
|
June 27, 2022
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease
Priti Gros, Susan H Fox, Anthony E Lang
The Neurologist
|
May 3, 2012
Improvement of apathy after levofloxacin treatment: an N-of-1 study
Melissa Jo Armstrong, Susan H Fox, Connie Marras
Expert Opinion on Emerging Drugs
|
May 6, 2020
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 5, 2009
Serotonin and Parkinson's disease: On movement, mood, and madness
Susan H Fox, Rosalind Chuang, Jonathan M Brotchie
Movement Disorders Clinical Practice
|
January 10, 2022
MPTP Parkinsonism and Implications for Understanding Parkinson's Disease
Sohaila AlShimemeri, Daniel G Di Luca, Susan H Fox
Expert Opinion on Emerging Drugs
|
August 23, 2014
Emerging drugs for levodopa-induced dyskinesia
Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox
CNS Drugs
|
October 16, 2016
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas, Marta Ruiz-Lopez, Susan H Fox
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 29, 2006
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure
Susan H Fox, Anthony E Lang, Jonathan M Brotchie
Page
of 18
Search research articles
Search
Showing results (41-50 of 178) with videos related to
Sort By:
Page
of 18
Progress in Neurobiology
|
September 1, 2011
The serotonergic system in Parkinson's disease
Philippe Huot, Susan H Fox, Jonathan M Brotchie
Neurologic Clinics
|
April 4, 2025
Experimental Therapeutics in Parkinson's Disease: A Review
Priti Gros, Laura Armengou Garcia, Susan H Fox
JAMA Neurology
|
June 27, 2022
Commentary on Long-term Effectiveness of Adjuvant Treatment in Parkinson Disease
Priti Gros, Susan H Fox, Anthony E Lang
The Neurologist
|
May 3, 2012
Improvement of apathy after levofloxacin treatment: an N-of-1 study
Melissa Jo Armstrong, Susan H Fox, Connie Marras
Expert Opinion on Emerging Drugs
|
May 6, 2020
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Sohaila AlShimemeri, Susan H Fox, Naomi P Visanji
Movement Disorders : Official Journal of the Movement Disorder Society
|
May 5, 2009
Serotonin and Parkinson's disease: On movement, mood, and madness
Susan H Fox, Rosalind Chuang, Jonathan M Brotchie
Movement Disorders Clinical Practice
|
January 10, 2022
MPTP Parkinsonism and Implications for Understanding Parkinson's Disease
Sohaila AlShimemeri, Daniel G Di Luca, Susan H Fox
Expert Opinion on Emerging Drugs
|
August 23, 2014
Emerging drugs for levodopa-induced dyskinesia
Amaal Al Dakheel, Isabelle Beaulieu-Boire, Susan H Fox
CNS Drugs
|
October 16, 2016
Novel Levodopa Formulations for Parkinson's Disease
Maria Eliza Freitas, Marta Ruiz-Lopez, Susan H Fox
Movement Disorders : Official Journal of the Movement Disorder Society
|
July 29, 2006
Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure
Susan H Fox, Anthony E Lang, Jonathan M Brotchie
Page
of 18